N
GMAB icon

Nuveen’s Genmab GMAB Stock Holding History

Nuveen’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-684,858
Closed -$24.8M – 3343
2022
Q1 		$24.8M Sell
684,858
-8,900
-1% -$305K 0.01% 1049
2021
Q4 		$27.4M Sell
693,758
-16,565
-2% -$691K 0.01% 1037
2021
Q3 		$31M Buy
710,323
+17,381
+3% +$780K 0.01% 967
2021
Q2 		$28.3M Buy
692,942
+192,502
+38% +$7.43M 0.01% 1103
2021
Q1 		$16.4M Sell
500,440
-8,060
-2% -$303K 0.01% 1463
2020
Q4 		$20.7M Sell
508,500
-80,256
-14% -$3M 0.01% 1247
2020
Q3 		$21.6M Buy
+588,756
New +$21.3M 0.01% 1012

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nuveen's GMAB Position: Q2 2022 in Review

Nuveen sold out of Genmab (GMAB) in Q2 2022, closing a stake of 684,858 shares — an estimated $24.8M sold.

Nuveen first reported a position in GMAB in Q3 2020 and held it in 7 quarters. The position peaked at $31M in Q3 2021. 180 funds tracked by Wall St. Rank hold GMAB as of Q2 2022.

  • Nuveen reported no remaining Genmab position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 684,858 Genmab shares in Q2 2022, an estimated $24.8M.
  • Nuveen first reported a position in Genmab in Q3 2020 and held it in 7 quarters.
  • Nuveen's Genmab position peaked at $31M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Genmab as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.